News >

Real-World Analysis Shows Cost-Reducing Benefit With CAR-T in Relapsed DLBCL

Jessica Hergert
Published: Friday, Dec 20, 2019

Karl M. Kilgore, PhD

Karl M. Kilgore, PhD

Results of real-world analysis presented at the 2019 ASH Annual Meeting demonstrated that patients with diffuse large B-cell lymphoma (DLBCL) who are older and with multiple comorbidities can successfully be treated with CAR T-cell therapy, and hospitalization rates and costs were lower posttreatment compared with before patients received therapy, said Karl M. Kilgore, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication